Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177587 | 0.80 | ALDH1A1 (0.44) | — | |
| SCHEMBL1640359 | 0.79 | ALDH1A1 (0.34) | NPY5RKITGAACHRM5TP53 | |
| SCHEMBL50995 | 0.79 | CA12 (0.40) | KITGAACHRM5TP53THRB | |
| SCHEMBL761873 | 0.78 | NOS1 (0.46) | GAA | |
| SCHEMBL4902068 | 0.77 | TP53 (0.34) | KITGAACHRM5TP53THRB | |
| Fluoride SCHEMBL27351745 | 0.76 | GAA (0.34) | NPY5RKITGAACHRM5TP53 | |
| Hydrochloric Acid SCHEMBL27291930 | 0.76 | GAA (0.34) | NPY5RKITGAACHRM5TP53 | |
| SCHEMBL21993160 | 0.76 | GAA (0.34) | KITGAACHRM5TP53THRB | |
| SCHEMBL23497255 | 0.75 | KMT2A (0.44) | GAA | |
| SCHEMBL14969351 | 0.74 | CA12 (0.39) | NPY5RKITGAATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | SEED THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| EP-4704836-A1 | HETEROAROMATIC INDOLESULFONAMIDES | Seed Therapeutics, Inc (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3728194-B1 | QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | OTAGO INNOVATION LTD (NZ) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025104079-A1 | SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250115687-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORP USA (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025075722-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-0719266-A1 | HETEROARYLAMINO AND HETEROARYLSULFONAMIDO SUBSTITUTED 3-BENZYLAMINOMETHYL PIPERIDINES AND RELATED COMPOUNDS | PFIZER INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5500405-A | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0659181-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1995007908-A1 | HETEROARYLAMINO AND HETEROARYLSULFONAMIDO SUBSTITUTED 3-BENZYLAMINOMETHYL PIPERIDINES AND RELATED COMPOUNDS | PFIZER INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5272128-A | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0511826-A2 | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | NPY5R 2222/4885KIT 4736/4885GAA 940/4885 |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | DCAF1, DCAF15, DDX39B | NPY5R 3731/4885KIT 2898/4885GAA 4707/4885 |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | NPY5R 4443/4885KIT 1162/4885GAA 1860/4885 |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | CACNA1A, CACNA1E, CACNA1S | NPY5R 655/4885KIT 4709/4885GAA 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.